Postoperative adjuvant hepatic arterial infusion chemotherapy with gemcitabine-cisplatin sequential capecitabine combined with PDL1 inhibitors in resected high-risk intrahepatic cholangiocarcinom: study protocol for a prospective, multicenter, single
This study has been approved by the Ethics Committee of West China Hospital of Sichuan University (IRB No. 2024-1982). The trial was prospectively registered at Chinese Clinical Trial Registry (http://www.chictr.org.cn, ChiCTR2500097319) on February 17, 2025.
Authors
- Qingyun Xie (ORCID: https://orcid.org/0009-0003-1621-7589)
- Xin Zheng (ORCID: https://orcid.org/0000-0001-5285-4989)
- Chang Liu (ORCID: https://orcid.org/0000-0003-3879-7302)
- Yu Haipeng
- Jiayin Yang (ORCID: https://orcid.org/0000-0002-9048-2095)
- Ying Yang (ORCID: https://orcid.org/0000-0002-2894-4877)
- Tao Lv (ORCID: https://orcid.org/0000-0002-6516-0393)
- Hong Wu
- Hui Zhang (ORCID: https://orcid.org/0009-0003-9921-1851)
Institutions
- Army Medical University (CN)
- Sichuan University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fonc.2025.1584007
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00